PRL and cancer: In contrast to the enhanced CD44 fluorescence intensity per cell basis, the percentage of cancer cells expressing CD44 was not different over a 2-day period of observation between control and prolactin treatment (Figure 3C), suggesting that prolactin did not induce but enhanced/upregulated CD44 expression in cancer cells.